Next-Generation Oncology Devices And Solutions Market Report 2026

Next-Generation Oncology Devices And Solutions Market Overview

• Next-Generation Oncology Devices And Solutions market size has reached to $16.41 billion in 2025 • Expected to grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.4% • Growth Driver: Rising Cancer Prevalence Driving Demand For The Market Due To Growing Need For Early Detection And Personalized Care • Market Trend: Integrated DNA Technologies Unveils Innovative NGS Solution • North America was the largest region in 2025.

What Is Covered Under Next-Generation Oncology Devices And Solutions Market?

Next-generation oncology devices and solutions refer to advanced technologies and tools designed to detect, diagnose, monitor, and treat various types of cancer with greater precision and speed. Their purpose is to enable personalized cancer care by leveraging innovations such as next-generation sequencing, digital pathology, and targeted therapies to improve patient outcomes. The main cancer types addressed by next-generation oncology devices and solutions include breast cancer, cervical cancer, colorectal cancer, and lung cancer. Breast cancer is a disease in which cells in the breast grow uncontrollably, often forming a tumor that can be felt as a lump or detected through imaging. These solutions utilize technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), DNA microarrays, multiplexing, and other advanced methods and are applied in areas such as screening and early detection, prognostics and monitoring, therapy selection, and recurrence monitoring, among others. The key end users include hospitals and clinics, diagnostic laboratories, academic and research institutions, and others.

What Is The Next-Generation Oncology Devices And Solutions Market Growth Forecast?

The next-generation oncology devices and solutions market size is expected to see rapid growth in the next few years. It will grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatment, rising investments in genomic diagnostics, expansion of early screening programs, growing integration of ai in oncology workflows, advancements in biomarker-based cancer management. Major trends in the forecast period include increasing adoption of precision oncology platforms, rising use of ngs-based cancer diagnostics, growing integration of digital pathology solutions, expansion of personalized cancer treatment approaches, enhanced focus on early detection technologies.

Global Next-Generation Oncology Devices And Solutions Market Segmentation

1) By Cancer Type: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), DNA Microarrays, Multiplexing, Other Technologies 3) By Application: Screening And Early Detection, Prognostics And Monitoring, Therapy Selection, Recurrence Monitoring, Other Applications 4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Uses Subsegments: 1) By Breast Cancer: Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer 2) By Cervical Cancer: Squamous Cell Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma 3) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Metastatic Colorectal Cancer 4) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Squamous Cell Lung Carcinoma

What Is The Driver Of The Next-Generation Oncology Devices And Solutions Market?

The increasing prevalence of cancer is expected to propel the growth of the next-generation oncology devices and solutions market going forward. Cancer is a disease in which abnormal cells grow uncontrollably and can spread to other parts of the body, disrupting normal bodily functions. The rising prevalence of cancer is largely due to aging populations, as the risk of developing cancer increases with age. Next-generation oncology devices and solutions help manage the rising prevalence of cancer by enabling earlier detection, more precise diagnosis, and personalized treatment. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit organization, it is estimated that cancer will account for over 611,000 fatalities in the United States, equating to more than 1,600 cancer-related deaths daily. Therefore, the increasing prevalence of cancer will drive the growth of the next-generation oncology devices and solutions industry.

Key Players In The Global Next-Generation Oncology Devices And Solutions Market

Major companies operating in the next-generation oncology devices and solutions market are Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Elekta AB, Myriad Genetics Inc., Takara Bio USA Inc., NeoGenomics Inc., Guardant Health Inc., Accuray Incorporated, SOPHiA GENETICS SA, Paige.AI Inc., Deep Bio Inc., Lucida Medical Ltd.

Global Next-Generation Oncology Devices And Solutions Market Trends and Insights

Major companies in the next-generation oncology devices and solutions market are focusing on technological advancements such as next-generation sequencing (NGS) target enrichment solutions to improve the detection of rare genetic variants, enhance sequencing accuracy, and accelerate cancer diagnosis and treatment decisions. Next-generation sequencing (NGS) target enrichment solutions are techniques that selectively capture and concentrate specific regions of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) for sequencing, enabling more accurate and efficient analysis of genetic variants associated with diseases such as cancer. For instance, in April 2025, Integrated DNA Technologies (IDT), a US-based biotechnology company, unveiled the xGen Hybridization and Wash v3 Kit, a transformative hybridization capture solution designed to accelerate cancer research by streamlining next-generation sequencing (NGS) workflows. This innovative kit significantly reduces the hybridization time to just one hour, enabling researchers to complete sample preparation and proceed to sequencing within a single workday. By eliminating the need for heated buffers and cutting hands-on time by 20%, the solution is highly automation-friendly and well-suited for high-throughput applications.

What Are Latest Mergers And Acquisitions In The Next-Generation Oncology Devices And Solutions Market?

In July 2024, Hologic, a US-based medical technology company, acquired Endomag for an undisclosed amount. With this acquisition, Hologic aims to strengthen its breast cancer surgery portfolio by integrating Endomag's innovative surgical guidance products for more precise and effective cancer care. Endomag is a UK-based medical device manufacturer specializing in surgical guidance products for breast cancer care.

Regional Outlook

North America was the largest region in the next-generation oncology devices and solutions market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Next-Generation Oncology Devices And Solutions Market?

The next-generation oncology devices and solutions market consists of revenues earned by entities by providing services such as cancer genomic profiling and sequencing, personalized treatment planning, remote patient monitoring and tele-oncology, and early cancer detection and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation oncology devices and solutions market also includes sales of liquid biopsy kits, companion diagnostic tests, digital pathology systems, cancer biomarker detection assays, and targeted therapy monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.